DDInter484 DDInter1840
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) binds {v} (Gene) BMX
BMX {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) upregulates {v} (Gene) CBLB
CBLB {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) binds {v} (Gene) TXK
TXK {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) upregulates {v} (Gene) WWOX
WWOX {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) downregulates {v} (Gene) HRAS
HRAS {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib {u} (Compound) upregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) covaries with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Dasatinib (Compound) binds BMX (Gene) and BMX (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) upregulates CBLB (Gene) and CBLB (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) binds TXK (Gene) and TXK (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) upregulates WWOX (Gene) and WWOX (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) downregulates HRAS (Gene) and HRAS (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dasatinib (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) covaries with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)